Approvals/TGA/OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion

Approved

STANDARD

OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion

Eli Lilly Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: 8412cab4f63ac7fa
Product Name: OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion
Artg Id: 391349
Artg Name: OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion
Sponsor: Eli Lilly Australia Pty Ltd
Company Detail Path: /organization/eli-lilly-australia-pty-ltd
Artg Date: 2023-09-27
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE

Approved

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

8412cab4f63ac7fa

Type

Standard